文献速递内脏/肾动脉与血管畸形

6-F与8-F Indigo血栓清除系统治疗急性肾内脏动脉闭塞的初步经验

Initial Experience With the 6-F and 8-F Indigo Thrombectomy System for Acute Renovisceral Occlusive Events.
PubMed 文献 · J Endovasc Ther · 2017-05-26

本研究评估新型大口径Indigo血栓清除导管治疗急性肾内脏动脉闭塞的安全性与有效性。7例患者(6条肾动脉、3条肠系膜上动脉)接受无溶栓的真空辅助血栓清除,技术成功率100%,无重大不良事件,但术后血红蛋白和红细胞压积显著下降。

要点

  • 大口径Indigo导管无溶栓治疗急性肾内脏动脉闭塞技术成功率100%。
  • 术后血红蛋白和红细胞压积显著下降,需警惕抽吸相关失血。
  • 分支支架桥接处闭塞常规经肱动脉使用8-F导管,自体肾动脉用6-F导管。

核心结论

  • 新型大口径Indigo血栓清除导管是急性肾内脏动脉闭塞有效且安全的一线无溶栓治疗,但使用者应充分认识抽吸过程中的潜在失血。

研究设计与样本

  • 2015年11月至2016年,连续7例急性肾内脏动脉闭塞患者(平均年龄65±5岁,5例男性)接受6-F和8-F真空辅助血栓清除导管治疗。
  • 闭塞血管包括6条肾动脉和3条肠系膜上动脉,其中5处血栓位于分支支架桥接处。
  • 平均病变长度63±36 mm,肠系膜上动脉和所有桥接支架常规经肱动脉使用8-F导管,自体肾动脉使用6-F抽吸导管。

主要发现

  • 技术成功率为100%,无重大不良事件或致命性出血。
  • 平均抽吸血液量为219±97 mL。
  • 平均血红蛋白从术前13.1±2.1 g/dL降至术后11.6±2.2 g/dL(p=0.001),红细胞压积从39%±6%降至34%±6%(p<0.0001)。

关键数值与推荐

  • 技术成功定义为恢复顺行血流且无需溶栓或替代血栓清除/血运重建策略。
  • 安全终点为任何院内重大不良事件。

临床怎么用

  • 对于急性肾内脏动脉闭塞,可考虑使用大口径Indigo导管进行无溶栓的一线血栓清除。
  • 操作中应监测抽吸相关失血,术后复查血红蛋白和红细胞压积。

局限性

  • 样本量小(7例患者),仅为初步经验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine the safety and effectiveness of the new large-bore Indigo thrombectomy catheters to treat patients with acute renovisceral occlusion without the need of thrombolytic agents. METHODS: Between November 2015 and 2016, 7 consecutive patients (mean age 65±5 years; 5 men) with acute renovisceral artery occlusion were treated with the new large-bore (6-F and 8-F) vacuum-assisted thrombectomy catheters. The occluded vessels were 6 renal arteries and 3 superior mesenteric arteries (SMAs); 5 of the 9 thromboses were in bridging stent-grafts associated with branched endografts. Mean lesion length was 63±36 mm. For the SMA and all bridging stent-grafts, 8-F catheters are routinely used through a brachial access, whereas 6-F aspiration catheters were used in native renal arteries. Technical success was defined as restoration of antegrade blood flow without the need of lysis or alternative thrombectomy/revascularization strategies. Safety endpoints were any in-hospital major adverse events. Pre- and postoperative hemoglobin and hematocrit levels were compared. RESULTS: Technical success was 100% with no major adverse events or fatal bleeding. The mean amount of aspirated blood was 219±97 mL. The mean hemoglobin and hematocrit values were 13.1±2.1 g/dL and 39%±6% prior to and 11.6±2.2 g/dL (p=0.001) and 34%±6% (p<0.0001) directly after the intervention, respectively. CONCLUSION: The first assessment of the new large-bore Indigo thrombectomy catheters showed them to be an effective and safe lysis-free frontline therapy for acute renovisceral artery occlusion in a small cohort of patients. New users should be fully aware of the potential blood loss during aspiration.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Bisdas T, Stavroulakis K, Beropoulis E, et al. Initial Experience With the 6-F and 8-F Indigo Thrombectomy System for Acute Renovisceral Occlusive Events. J Endovasc Ther. 2017. PMID: 28548010. doi:10.1177/1526602817710492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。